Pinatuzumab vedotin
Pinatuzumab Vedotin[edit | edit source]
Pinatuzumab vedotin is an antibody-drug conjugate (ADC) designed for the treatment of certain types of cancer. It is a targeted therapy that combines a monoclonal antibody with a cytotoxic agent, specifically designed to deliver the drug directly to cancer cells, thereby minimizing damage to normal cells.
Mechanism of Action[edit | edit source]
Pinatuzumab vedotin consists of a monoclonal antibody that targets the CD22 antigen, which is commonly expressed on the surface of B-cell malignancies. The antibody is linked to a cytotoxic agent, monomethyl auristatin E (MMAE), via a protease-cleavable linker. Once the ADC binds to the CD22 antigen on the surface of a cancer cell, it is internalized and the linker is cleaved, releasing MMAE into the cell. MMAE disrupts the microtubule network, leading to cell cycle arrest and apoptosis.
Clinical Development[edit | edit source]
Pinatuzumab vedotin has been evaluated in clinical trials for the treatment of non-Hodgkin lymphoma (NHL), particularly in patients with relapsed or refractory disease. The ADC has shown promise in targeting CD22-positive B-cell malignancies, offering a potential therapeutic option for patients who have exhausted other treatments.
Side Effects[edit | edit source]
As with many cancer therapies, pinatuzumab vedotin can cause a range of side effects. Common adverse effects include peripheral neuropathy, fatigue, nausea, and myelosuppression. The severity of side effects can vary depending on the dosage and the individual patient's response to the treatment.
Future Directions[edit | edit source]
Research is ongoing to explore the full potential of pinatuzumab vedotin in combination with other therapies, as well as its efficacy in different subtypes of B-cell malignancies. The development of ADCs like pinatuzumab vedotin represents a significant advancement in the field of targeted cancer therapy, offering hope for more effective and less toxic treatment options.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
